Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of TH104 (Buccal Nalmefene) in Healthy Volunteers
NCT06198686Phase 1Completed
- Sponsor
- Tharimmune, Inc.
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nalmefene in primary biliary cholangitis (PBC) (2 arms), sponsored by Tharimmune, Inc. Primary endpoint: Area Under the Plasma Concentration Versus Time Curve at 4 days. Started Jan 2024; status: completed.
02
Drugs
nalmefene
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06198686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06198686.